There is an inherent tension in approving drugs: do we want to expand access to patients sooner, or do we want to more robustly confirm the safety profile of the new drug? A new paper analyzes this problem and finds the FDA currently favors a speedy review.

See the source article by following the link below:
There is an inherent tension in approving drugs: do we want to expand access to patients sooner, or do we want to more robustly confirm the safety profile of the new drug? A new paper analyzes this problem and finds the FDA currently favors a speedy review.